Glucose Transporter-1 and Tumor Size Affect Assessment in Gastric Cancer on SPECT
Main Article Content
Abstract
Background: GLUT-1 expression is the crucial parameter affecting gastric cancer 18-FDG absorption is still controversial. This study is to explore the significance of GLUT-1 in gastric cancer 18-FDG SPECT.
Material/Methods: The gastric cancer samples of 134 patients with preoperative 18-FDG SPECT were assessed by GLUT-1 immunohistochemical staining. The clinicopathological information of enrolled patients were analyzed with univariate and regression analyses.
Results: The SUVmax in positive GLUT-1 expression was significantly higher than that in negative expression (5.136±3.088 vs 4.003±3.604, p=0.004). Tumor diameter (OR 1.415, p=0.005) and GLUT-1 expression level(OR 1.683, p=0.041) were the factors associated with imaging results by visual assessment, independently. Tumor diameter was independent factor associated with SUVmax in positive imaging cases (p=0.029). Tumor diameter(p=0.003) and tumor differentiation(p=0.026) were independent factors related to SUVmax in differentiated carcinoma cases.
Conclusions: GLUT-1 expression level is major factor determining 18-FDG uptake of gastric cancer on SPECT. It is necessary to verify the result with PET/CT. Further investigation on analysis GLUT-1 expression in lesions of gastric cancer metastases and recurrences is required.
Keywords:
Glucose Transporter Type 1, Gastric cancer, FDG, SPECT
Article Details
How to Cite
YIN, Chenqing; NAN, Yule; YANG, Ju.
Glucose Transporter-1 and Tumor Size Affect Assessment in Gastric Cancer on SPECT.
Medical Research Archives, [S.l.], v. 11, n. 9, sep. 2023.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/4489>. Date accessed: 23 nov. 2024.
doi: https://doi.org/10.18103/mra.v11i9.4489.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. Mar 2015;65(2):87-108. doi:10.3322/caac.21262
2. Marano L, Polom K, Patriti A, et al. Surgical management of advanced gastric cancer: An evolving issue. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Jan 2016;42(1):18-27. doi:10.1016/j.ejso.2015.10.016
3. Mortensen MB. Novel imaging strategies for upper gastrointestinal tract cancers. Expert review of gastroenterology & hepatology. Mar 2015;9(3):295-303. doi:10.1586/17474124.2015.959928
4. Gauthe M, Richard-Molard M, Cacheux W, et al. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Jun 2015;47(6):443-54. doi:10.1016/j.dld.2015.02.005
5. Yun M. Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT. Journal of gastric cancer. Mar 2014;14(1):1-6. doi:10.5230/jgc.2014.14.1.1
6. Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/ computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health technology assessment. Sep 2011;15(35):1-192, iii-iv. doi:10.3310/hta15350
7. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nuclear medicine communications. Mar 2008;29(3):193-207. doi:10.1097/MNM.0b013e3282f3a515
8. Gholamrezanejhad A, Mirpour S, Mariani G. Future of nuclear medicine: SPECT versus PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Jul 2009;50(7):16N-18N.
9. Histed SN, Lindenberg ML, Mena E, Turkbey B, Choyke PL, Kurdziel KA. Review of functional/anatomical imaging in oncology. Nuclear medicine communications. Apr 2012; 33(4):349-61. doi:10.1097/MNM.0b013e32834ec8a5
10. Yin CQ, Nan YL, Cheng ZJ, Yin QZ, Lu T. Analysis of 18F-FDG maximum standardized uptake value in gastric cancer with coincidence imaging. Chin J Nucl Med Mol Imaging. 2014;34(1):30-3.
11. Abikhzer G, Keidar Z. SPECT/CT and tumour imaging. European journal of nuclear medicine and molecular imaging. May 2014;41 Suppl 1:S67-80. doi:10.1007/s00259-013-2534-4
12. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nuclear medicine and biology. Jan 2001;28(1):1-4.
13. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Annals of nuclear medicine. Nov 2006;20(9):597-604.
14. Alakus H, Batur M, Schmidt M, et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nuclear medicine communications. Jun 2010;31(6):532-8. doi:10.1097/MNM.0b013e32833823ac
15. Wei B, Chen B, Kou QL, et al. [Glut1 expression and its relation with the absorption of 18F-FDG in stomach cancer]. Zhonghua yi xue za zhi. Jul 2 2004;84(13):1105-7.
16. Takebayashi R, Izuishi K, Yamamoto Y, et al. [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer. Journal of experimental & clinical cancer research : CR. 2013;32:34. doi:10.1186/1756-9966-32-34
17. Yin C, Nan Y, Lu T, Cheng Z, Cai Y. Clinicopathological Parameters Influence Assessment of FDG SPECT in Gastric Cancer. Hepato-gastroenterology. May 2015;62(139): 762-5.
18. Hamilton S, Aaltonen L. Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. IARCP; 2000.
19. Park MJ, Lee WJ, Lim HK, Park KW, Choi JY, Kim BT. Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdominal imaging. Jul 2009;34(4):441-7. doi:10.1007/s00261-008-9424-4
20. Xiao Y-j, Zhang X-s, Xu W-p, Tang A-s, Qiao S-x. The value of 18F-FDG PET in estimation of recurrence and metastasis of gastric carcinoma. Chin J Nucl Med. 2004;24(3): 149-151. doi:10.3760/cma.j.issn.2095-2848.2004.03.007
21. Shoda H, Kakugawa Y, Saito D, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. British journal of cancer. Dec 3 2007;97(11):1493-8. doi:10.1038/sj.bjc.6604062
22. Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. May 2009;35(5):449-55. doi:10.1016/j.ejso.2008.11.010
23. Smyth E, Schoder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. Nov 15 2012;118(22):5481-8. doi:10.1002/cncr.27550
24. Yan C, Yan M, Zhu ZG. [Application and value of preoperative staging in gastric cancer]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2013;16(2):114-117. doi:10.3760/cma.j.issn.1671-0274.2013.02.005
25. Cui JX, Li T, Xi HQ, Wei B, Chen L. Evaluation of 18F-FDG PET/CT in preoperative staging of gastric cancer: a meta-analysis. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2013;16(5):418-424. doi:10.3760/cma.j.issn.1671-0274.2013.05.005
26. Park JC, Lee JH, Cheoi K, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. European journal of nuclear medicine and molecular imaging. Jul 2012;39(7): 1107-16. doi:10.1007/s00259-012-2116-x
27. Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for FDG-PET scanning in the staging of gastric cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Mar 5 2015;doi:10.2967/jnumed.114.150946
28. Choi BH, Song HS, An YS, Han SU, Kim JH, Yoon JK. Relation between fluorodeoxyglucose uptake and glucose transporter-1 expression in gastric signet ring cell carcinoma. Nuclear medicine and molecular imaging. Mar 2011;45(1):30-5. doi:10.1007/s13139-010-0058-4
29. Geng J-h, Chen Y-m, Chen S-z, Tian J-h, He Y-j, Qiao S-z. Comparison of dual-head coincidence imaging SUV with PET imaging SUV:a phantom study. Chin J Nucl Med. 2004;24(5):308-309. doi:10.3760/cma.j.issn.2095-2848.2004.05.017
30. Huang K-m, Feng Y-l, He X-h, et al. Comparison of the different reconstruction algorithms for Philips GEMINI PET/CT. Chin J Med Imaging Technol. 2010;26(2):365-368.
31. Geng J-h, Chen S-z, Chen Y-m, Zhu J-q. Determination of pixel radioactive concentration in dual-head coincidence 18F-FDG PET imaging. Chin J Nucl Med. 2003;23(2):118-120. doi:10.3760/cma.j.issn.2095-2848.2003.02.018
32. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepato-gastroenterology. Jul-Aug 1999;46(28):2683-9.
33. Rho M, Kim J, Jee CD, et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer research. Jan-Feb 2007;27(1A): 251-8.
34. Lee JW, Lee SM, Lee MS, Shin HC. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. European journal of nuclear medicine and molecular imaging. Sep 2012;39(9): 1425-34. doi:10.1007/s00259-012-2164-2
35. Sawayama H, Ishimoto T, Watanabe M, et al. High expression of glucose transporter 1 on primary lesions of esophageal squamous cell carcinoma is associated with hematogenous recurrence. Annals of surgical oncology. May 2014;21(5):1756-62. doi:10.1245/s10434-013-3371-1
36. Goos JA, de Cuba EM, Coupe VM, et al. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Annals of surgery. Jan 5 2015;doi:10.1097/SLA.0000000000001109
37. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. Aug 1 2001;92(3):634-41.
38. Yin C, Gao B, Yang J, Wu J. Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer. Medical science monitor basic research. Mar 23 2020;26:e920778. doi:10.12659/msmbr.920778
2. Marano L, Polom K, Patriti A, et al. Surgical management of advanced gastric cancer: An evolving issue. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. Jan 2016;42(1):18-27. doi:10.1016/j.ejso.2015.10.016
3. Mortensen MB. Novel imaging strategies for upper gastrointestinal tract cancers. Expert review of gastroenterology & hepatology. Mar 2015;9(3):295-303. doi:10.1586/17474124.2015.959928
4. Gauthe M, Richard-Molard M, Cacheux W, et al. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Jun 2015;47(6):443-54. doi:10.1016/j.dld.2015.02.005
5. Yun M. Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT. Journal of gastric cancer. Mar 2014;14(1):1-6. doi:10.5230/jgc.2014.14.1.1
6. Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/ computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health technology assessment. Sep 2011;15(35):1-192, iii-iv. doi:10.3310/hta15350
7. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nuclear medicine communications. Mar 2008;29(3):193-207. doi:10.1097/MNM.0b013e3282f3a515
8. Gholamrezanejhad A, Mirpour S, Mariani G. Future of nuclear medicine: SPECT versus PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Jul 2009;50(7):16N-18N.
9. Histed SN, Lindenberg ML, Mena E, Turkbey B, Choyke PL, Kurdziel KA. Review of functional/anatomical imaging in oncology. Nuclear medicine communications. Apr 2012; 33(4):349-61. doi:10.1097/MNM.0b013e32834ec8a5
10. Yin CQ, Nan YL, Cheng ZJ, Yin QZ, Lu T. Analysis of 18F-FDG maximum standardized uptake value in gastric cancer with coincidence imaging. Chin J Nucl Med Mol Imaging. 2014;34(1):30-3.
11. Abikhzer G, Keidar Z. SPECT/CT and tumour imaging. European journal of nuclear medicine and molecular imaging. May 2014;41 Suppl 1:S67-80. doi:10.1007/s00259-013-2534-4
12. Smith TA. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation. Nuclear medicine and biology. Jan 2001;28(1):1-4.
13. Yamada A, Oguchi K, Fukushima M, Imai Y, Kadoya M. Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Annals of nuclear medicine. Nov 2006;20(9):597-604.
14. Alakus H, Batur M, Schmidt M, et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nuclear medicine communications. Jun 2010;31(6):532-8. doi:10.1097/MNM.0b013e32833823ac
15. Wei B, Chen B, Kou QL, et al. [Glut1 expression and its relation with the absorption of 18F-FDG in stomach cancer]. Zhonghua yi xue za zhi. Jul 2 2004;84(13):1105-7.
16. Takebayashi R, Izuishi K, Yamamoto Y, et al. [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer. Journal of experimental & clinical cancer research : CR. 2013;32:34. doi:10.1186/1756-9966-32-34
17. Yin C, Nan Y, Lu T, Cheng Z, Cai Y. Clinicopathological Parameters Influence Assessment of FDG SPECT in Gastric Cancer. Hepato-gastroenterology. May 2015;62(139): 762-5.
18. Hamilton S, Aaltonen L. Pathology and genetics of tumours of the digestive system. World Health Organization classification of tumours. IARCP; 2000.
19. Park MJ, Lee WJ, Lim HK, Park KW, Choi JY, Kim BT. Detecting recurrence of gastric cancer: the value of FDG PET/CT. Abdominal imaging. Jul 2009;34(4):441-7. doi:10.1007/s00261-008-9424-4
20. Xiao Y-j, Zhang X-s, Xu W-p, Tang A-s, Qiao S-x. The value of 18F-FDG PET in estimation of recurrence and metastasis of gastric carcinoma. Chin J Nucl Med. 2004;24(3): 149-151. doi:10.3760/cma.j.issn.2095-2848.2004.03.007
21. Shoda H, Kakugawa Y, Saito D, et al. Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. British journal of cancer. Dec 3 2007;97(11):1493-8. doi:10.1038/sj.bjc.6604062
22. Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K. FDG-PET has no definite role in preoperative imaging in gastric cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. May 2009;35(5):449-55. doi:10.1016/j.ejso.2008.11.010
23. Smyth E, Schoder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. Nov 15 2012;118(22):5481-8. doi:10.1002/cncr.27550
24. Yan C, Yan M, Zhu ZG. [Application and value of preoperative staging in gastric cancer]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2013;16(2):114-117. doi:10.3760/cma.j.issn.1671-0274.2013.02.005
25. Cui JX, Li T, Xi HQ, Wei B, Chen L. Evaluation of 18F-FDG PET/CT in preoperative staging of gastric cancer: a meta-analysis. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2013;16(5):418-424. doi:10.3760/cma.j.issn.1671-0274.2013.05.005
26. Park JC, Lee JH, Cheoi K, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. European journal of nuclear medicine and molecular imaging. Jul 2012;39(7): 1107-16. doi:10.1007/s00259-012-2116-x
27. Kaneko Y, Murray WK, Link E, Hicks RJ, Duong C. Improving patient selection for FDG-PET scanning in the staging of gastric cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Mar 5 2015;doi:10.2967/jnumed.114.150946
28. Choi BH, Song HS, An YS, Han SU, Kim JH, Yoon JK. Relation between fluorodeoxyglucose uptake and glucose transporter-1 expression in gastric signet ring cell carcinoma. Nuclear medicine and molecular imaging. Mar 2011;45(1):30-5. doi:10.1007/s13139-010-0058-4
29. Geng J-h, Chen Y-m, Chen S-z, Tian J-h, He Y-j, Qiao S-z. Comparison of dual-head coincidence imaging SUV with PET imaging SUV:a phantom study. Chin J Nucl Med. 2004;24(5):308-309. doi:10.3760/cma.j.issn.2095-2848.2004.05.017
30. Huang K-m, Feng Y-l, He X-h, et al. Comparison of the different reconstruction algorithms for Philips GEMINI PET/CT. Chin J Med Imaging Technol. 2010;26(2):365-368.
31. Geng J-h, Chen S-z, Chen Y-m, Zhu J-q. Determination of pixel radioactive concentration in dual-head coincidence 18F-FDG PET imaging. Chin J Nucl Med. 2003;23(2):118-120. doi:10.3760/cma.j.issn.2095-2848.2003.02.018
32. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepato-gastroenterology. Jul-Aug 1999;46(28):2683-9.
33. Rho M, Kim J, Jee CD, et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer research. Jan-Feb 2007;27(1A): 251-8.
34. Lee JW, Lee SM, Lee MS, Shin HC. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. European journal of nuclear medicine and molecular imaging. Sep 2012;39(9): 1425-34. doi:10.1007/s00259-012-2164-2
35. Sawayama H, Ishimoto T, Watanabe M, et al. High expression of glucose transporter 1 on primary lesions of esophageal squamous cell carcinoma is associated with hematogenous recurrence. Annals of surgical oncology. May 2014;21(5):1756-62. doi:10.1245/s10434-013-3371-1
36. Goos JA, de Cuba EM, Coupe VM, et al. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Annals of surgery. Jan 5 2015;doi:10.1097/SLA.0000000000001109
37. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. Aug 1 2001;92(3):634-41.
38. Yin C, Gao B, Yang J, Wu J. Glucose Transporter-1 (GLUT-1) Expression is Associated with Tumor Size and Poor Prognosis in Locally Advanced Gastric Cancer. Medical science monitor basic research. Mar 23 2020;26:e920778. doi:10.12659/msmbr.920778